Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathrin Eschke

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Journal of Virology|January 12, 2022
Rapid SARS-CoV-2 Adaptation to Available Cellular ProteasesM Zeeshan Chaudhry, Kathrin Eschke, Markus Hoffmann, et al.
Frontiers in Pharmacology|August 11, 2023
<i>In vitro</i> and <i>in vivo</i> effects of <i>Pelargonium sidoides DC.</i> root extract EPs<sup>®</sup> 7630 and selected constituents against SARS-CoV-2 B.1, Delta AY.4/AY.117 and Omicron BA.2Jackson Emanuel, Jan Papies, Celine Galander, et al.
Plos One|August 2, 2021
Identification of cell lines CL-14, CL-40 and CAL-51 as suitable models for SARS-CoV-2 infection studiesClaudia Pommerenke, Ulfert Rand, Cord C Uphoff, et al.
Frontiers in Immunology|August 9, 2024
A single-dose MCMV-based vaccine elicits long-lasting immune protection in mice against distinct SARS-CoV-2 variantsKristin Metzdorf, Henning Jacobsen, Yeonsu Kim, et al.
Cellular & Molecular Immunology|January 7, 2022
MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccinationYeonsu Kim, Xiaoyan Zheng, Kathrin Eschke, et al.
Biorxiv : the Preprint Server for Biology|December 9, 2022
A single-dose MCMV-based vaccine elicits long-lasting immune protection in mice against distinct SARS-CoV-2 variantsKristin Metzdorf, Henning Jacobsen, Yeonsu Kim, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 27, 2022
Key benefits of dexamethasone and antibody treatment in COVID-19 hamster models revealed by single-cell transcriptomicsEmanuel Wyler, Julia M Adler, Kathrin Eschke, et al.
Iscience|March 17, 2023
Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by OmicronJakob Kreye, S Momsen Reincke, Stefan Edelburg, et al.
Science Signaling|April 25, 2023
Macrophage ACE2 is necessary for SARS-CoV-2 replication and subsequent cytokine responses that restrict continued virion releaseLarisa I Labzin, Keng Yih Chew, Kathrin Eschke, et al.
Nature Communications|March 12, 2021
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interfaceFederico Bertoglio, Doris Meier, Nora Langreder, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Journal of Virology|January 12, 2022
Rapid SARS-CoV-2 Adaptation to Available Cellular ProteasesM Zeeshan Chaudhry, Kathrin Eschke, Markus Hoffmann, et al.
Frontiers in Pharmacology|August 11, 2023
<i>In vitro</i> and <i>in vivo</i> effects of <i>Pelargonium sidoides DC.</i> root extract EPs<sup>®</sup> 7630 and selected constituents against SARS-CoV-2 B.1, Delta AY.4/AY.117 and Omicron BA.2Jackson Emanuel, Jan Papies, Celine Galander, et al.
Plos One|August 2, 2021
Identification of cell lines CL-14, CL-40 and CAL-51 as suitable models for SARS-CoV-2 infection studiesClaudia Pommerenke, Ulfert Rand, Cord C Uphoff, et al.
Frontiers in Immunology|August 9, 2024
A single-dose MCMV-based vaccine elicits long-lasting immune protection in mice against distinct SARS-CoV-2 variantsKristin Metzdorf, Henning Jacobsen, Yeonsu Kim, et al.
Cellular & Molecular Immunology|January 7, 2022
MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccinationYeonsu Kim, Xiaoyan Zheng, Kathrin Eschke, et al.
Biorxiv : the Preprint Server for Biology|December 9, 2022
A single-dose MCMV-based vaccine elicits long-lasting immune protection in mice against distinct SARS-CoV-2 variantsKristin Metzdorf, Henning Jacobsen, Yeonsu Kim, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 27, 2022
Key benefits of dexamethasone and antibody treatment in COVID-19 hamster models revealed by single-cell transcriptomicsEmanuel Wyler, Julia M Adler, Kathrin Eschke, et al.
Iscience|March 17, 2023
Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by OmicronJakob Kreye, S Momsen Reincke, Stefan Edelburg, et al.
Science Signaling|April 25, 2023
Macrophage ACE2 is necessary for SARS-CoV-2 replication and subsequent cytokine responses that restrict continued virion releaseLarisa I Labzin, Keng Yih Chew, Kathrin Eschke, et al.
Nature Communications|March 12, 2021
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interfaceFederico Bertoglio, Doris Meier, Nora Langreder, et al.
Pageof 3